Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers
Business Wire•14/10/2026•17:00 ET
0
Key Highlights
- ➤Aptar’s LuerVax and Spray Divider receive CE marking under EU Medical Device Regulation
- ➤LuerVax supports healthcare-professional administration of intranasal vaccines via compatible LuerLock syringe
- ➤Spray Divider enables two sequential sprays, one per nostril, in 200 µL and 500 µL sizes
- ➤CE-marked platform supports vaccine development from early clinical studies through commercialization
Expert Statements
Alex Theodorakis, President, Aptar Pharma Prescription
“Achieving CE marking for both LuerVax® and the Spray Divider is an important step in strengthening our support of vaccine developers worldwide”
Alex Theodorakis, President, Aptar Pharma Prescription
“Customers are increasingly seeking established device platforms that can support regulatory pathways and enable efficient clinical and commercial development.”
Alex Theodorakis, President, Aptar Pharma Prescription
“This CE marking reinforces Aptar's commitment to being a trusted partner throughout the vaccine development journey.”
Nektaria Karavas, Global Business Development Director - Vaccines and Antivirals, Aptar Pharma
“This achievement reflects Aptar's ongoing investment in innovative delivery solutions that address the evolving needs of vaccine developers”
Nektaria Karavas, Global Business Development Director - Vaccines and Antivirals, Aptar Pharma
“Our goal is to provide customers with the delivery technologies, expertise and regulatory support to bring the next generation of vaccines to market.”
Aptar Announces CE Marking for LuerVax(® )and Accompanying Spray Divider, Strengthening Support for Vaccine Developers
Milestone strengthens Aptar Pharma’s support for intranasal vaccine development from clinical studies through commercialization
Get started
Create a free account to read the full story.